Abstract
Background: There is no widely accepted treatment for non-alcoholic fatty liver disease (NAFLD) or its advanced form, non-alcoholic steatohepatitis (NASH).
Methods: We administered rosuvastatin (10 mg/day) for 1 year in patients with metabolic syndrome (MetS), NASH on liver biopsy and dyslipidaemia (but without diabetes or arterial hypertension). Patients also received lifestyle advice.
Results: We report preliminary results for 6 patients. The second biopsy (at the end of the study) showed complete resolution of NASH in 5 patients, while the 6th, which had no improvement, developed arterial hypertension and substantial rise in triglyceride levels during the study. We suspect alcohol abuse despite advice to abstain. Serum alanine transaminase (ALT) and aspartate transaminase (AST) activities were reduced by 76 and 61%, respectively (p < 0.001 for both), during treatment, while γ-glutamyl transpeptidase (γ-GT), and alkaline phosphatase (AP) showed smaller non significant reductions. Fasting plasma glucose and glycated haemoglobin (HbA1c) were significantly reduced (p<0.05). Lipid values were totally normalised and liver ultrasonography showed a complete resolution of NASH in 5 patients. Body mass index and waist circumference remained unchanged during the study. Thus, changes in liver pathology and function should be attributed to treatment with rosuvastatin. A substantial limitation of the study is the small number of patients.
Conclusions: These preliminary findings suggest that rosuvastatin could ameliorate NASH within a year of treatment in MetS patients with dyslipidaemia.
Keywords: Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, metabolic syndrome, dyslipidaemia, rosuvastatin.
Current Vascular Pharmacology
Title:Effect of Rosuvastatin on Non-alcoholic Steatohepatitis in Patients with Metabolic Syndrome and Hypercholesterolaemia: A Preliminary Report
Volume: 12 Issue: 3
Author(s): Konstantinos Kargiotis, Niki Katsiki, Vasilios G. Athyros, Olga Giouleme, Kalliopi Patsiaoura, Evangelia Katsiki, Dimitri P. Mikhailidis and Asterios Karagiannis
Affiliation:
Keywords: Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, metabolic syndrome, dyslipidaemia, rosuvastatin.
Abstract: Background: There is no widely accepted treatment for non-alcoholic fatty liver disease (NAFLD) or its advanced form, non-alcoholic steatohepatitis (NASH).
Methods: We administered rosuvastatin (10 mg/day) for 1 year in patients with metabolic syndrome (MetS), NASH on liver biopsy and dyslipidaemia (but without diabetes or arterial hypertension). Patients also received lifestyle advice.
Results: We report preliminary results for 6 patients. The second biopsy (at the end of the study) showed complete resolution of NASH in 5 patients, while the 6th, which had no improvement, developed arterial hypertension and substantial rise in triglyceride levels during the study. We suspect alcohol abuse despite advice to abstain. Serum alanine transaminase (ALT) and aspartate transaminase (AST) activities were reduced by 76 and 61%, respectively (p < 0.001 for both), during treatment, while γ-glutamyl transpeptidase (γ-GT), and alkaline phosphatase (AP) showed smaller non significant reductions. Fasting plasma glucose and glycated haemoglobin (HbA1c) were significantly reduced (p<0.05). Lipid values were totally normalised and liver ultrasonography showed a complete resolution of NASH in 5 patients. Body mass index and waist circumference remained unchanged during the study. Thus, changes in liver pathology and function should be attributed to treatment with rosuvastatin. A substantial limitation of the study is the small number of patients.
Conclusions: These preliminary findings suggest that rosuvastatin could ameliorate NASH within a year of treatment in MetS patients with dyslipidaemia.
Export Options
About this article
Cite this article as:
Kargiotis Konstantinos, Katsiki Niki, Athyros G. Vasilios, Giouleme Olga, Patsiaoura Kalliopi, Katsiki Evangelia, Mikhailidis P. Dimitri and Karagiannis Asterios, Effect of Rosuvastatin on Non-alcoholic Steatohepatitis in Patients with Metabolic Syndrome and Hypercholesterolaemia: A Preliminary Report, Current Vascular Pharmacology 2014; 12 (3) . https://dx.doi.org/10.2174/15701611113119990009
DOI https://dx.doi.org/10.2174/15701611113119990009 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot Topic (1): Update on Inflammatory Processes Governing Atherosclerotic Plaque Vulnerability and Reperfusion Injury (Guest Editors: Fabrizio Montecucco and Francois Mach)]
Current Pharmaceutical Biotechnology Enzyme Inhibition by Peroxynitrite-Mediated Tyrosine Nitration and Thiol Oxidation
Current Enzyme Inhibition Pharmacological Manipulation of Peripheral Vascular Resistance in Single Ventricle Patients (Stages I, II, and III of Palliation)
Current Vascular Pharmacology Clinical and Pharmacological Aspects of Inflammatory Demyelinating Diseases in Childhood: An Update
Current Neuropharmacology IgA Nephropathy: Clinical Significance of Urinary Proteins/Polypeptides Characterization
Current Proteomics Sequence Variants of the Ligand-Binding Domain of the Glucocorticoid Receptor Gene and their Functional Consequences on the Three- Dimensional Protein Structure
Current Medicinal Chemistry Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Biomarker for Acute Kidney Injury
Recent Patents on Biomarkers Incretins and Preservation of Endothelial Function
Cardiovascular & Hematological Agents in Medicinal Chemistry Neonatal Ultrasound in Transport
Current Pediatric Reviews Depression and Anxiety During Pregnancy: Clinical Aspects
Current Psychiatry Reviews Possible Role of Vascular Risk Factors in Alzheimer's Disease and Vascular Dementia
Current Pharmaceutical Design Rho-Kinase and RGS-Containing RhoGEFs as Molecular Targets for the Treatment of Erectile Dysfunction
Current Pharmaceutical Design Risk Factors for Cardiovascular Disease in Psoriasis: Relation to Inflammation Assessed by the Severity and Duration of Illness
Inflammation & Allergy - Drug Targets (Discontinued) Leveraging NMR and X-ray Data of the Free Ligands to Build Better Drugs Targeting Angiotensin II Type 1 G-Protein Coupled Receptor
Current Medicinal Chemistry Role of Antioxidants, Essential Fatty Acids, Carnitine, Vitamins, Phytochemicals and Trace Elements in the Treatment of Diabetes Mellitus and its Chronic Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets Stress-Induced Oxidative Changes in Brain
CNS & Neurological Disorders - Drug Targets Transcranial Doppler Ultrasonography: Current Status
Current Medical Imaging Giant Cell Arteritis – A Series of Cases and Review of Literature
Current Rheumatology Reviews The Effect of TNFα-Inhibitors on Cardiovascular Events in Patients with Rheumatoid Arthritis: An Updated Systematic Review of the Literature
Current Rheumatology Reviews Pharmacologic Role of Vitamin D Natural Products
Current Vascular Pharmacology